Dr. Daniel Sterman specializes in interventional pulmonology at the Perlmutter Cancer Center, using minimally invasive procedures to treat patients with thoracic malignancies.
Dr. Daniel Sterman treats patients with pleural mesothelioma, lung cancer and pleural effusion.
His work at the New York University Langone Medical Center has helped turn innovative research into new therapies for various lung diseases.
Sterman has spent the last two decades developing genetic immunotherapy, an alternative approach to controlling tumor growth and treating cancers such as mesothelioma and lung cancer.
He takes special interest in quickly bridging the gap between the latest laboratory advances and clinical treatment, offering hope where there previously was none for many patients.
“What I take satisfaction in is knowing I’m trying to make a difference, that maybe I’m making a difference,” he said. “We don’t have all the answers, but we’re trying to find them. It’s why I come back every day, excited about going to work.”
He also has experience in pleuroscopy, endobronchial stent placement and endobronchial brachytherapy. These are advanced techniques that treat thoracic malignancies.
Sterman joined Perlmutter at Langone Medical Center in 2015 as the director of the Multidisciplinary Pulmonary Oncology Program after almost 20 years at the University of Pennsylvania’s Abramson Cancer Center.
He graduated from Cornell University Medical School and completed a residency and fellowship at the University of Pennsylvania. He studied pulmonary and critical care and cardiovascular disease.
Sterman is certified by the American Board of Internal Medicine and is a professor at NYU in the Department of Cardiothoracic Surgery.
His patients also can see thoracic radiation oncologists, thoracic medical oncologists and thoracic surgeons, who all work together to formulate a customized approach to treatment.
Patients can opt to participate in clinical trials and novel research at Langone, which emphasizes a holistic approach to treatment.
Sterman treats all diseases of the lungs, along with tracheal stenosis, mediastinal disease, mediastinal tumors and mediastinal lymphadenopathy.
Sterman’s work has been recognized as both innovative and exemplary.
The National Institutes of Health presented him with its Clinical Associate Physician Award at the Abramson Cancer Center.
He has been a featured presenter several times at the annual International Symposium on Malignant Mesothelioma.
Sterman has been the lead investigator for the National Cancer Institute’s Program Project Grant — which has overseen several clinical trials — for almost two decades.
He also is the lead investigator for a mesothelioma gene therapy clinical trial at Langone Medical Center.
1 Cited Article Sources
Sponsored by The Peterson Firm, 1050 30th Street NW, Washington, DC 20007 © 2019 PleuralMesothelioma.com